EUVIMEDEUVIMED entdecken
Leserbrief

Quantifying Morbidity Risk Attributed to Red‐Cell Transfusion Volume in Optimally Transfused Patients With β‐Thalassemia

Khaled M Musallam iD, Angela Vitrano iD, Alessandro Inzerillo, Rosario Di Maggio iD, Rita Barone, Antonino Giangreco, Maria Concetta Renda iD, Emanuela Fecarotta, Antonio Troia, Antonino Giambona iD, Giovan Battista Ruffo, Efthymia Vlachaki iD und 8 weitere

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70100 ↗

Kurz gefasst

Leserbrief in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Khaled M Musallam und 19 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Medical City, Abu Dhabi, UAE. Hauptthemen laut MEDLINE: beta-Thalassemia, Erythrocyte Transfusion. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Agios Pharmaceuticals Inc., Agios Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-ThalassemiaErythrocyte TransfusionHumansMaleFemaleAdultFollow-Up StudiesHemoglobinsAdolescentMorbidityRisk FactorsMiddle AgedYoung Adult

Stichwörter der Autor:innen

complicationsthalassemiatransfusion

Substanzen

Hemoglobins

Autor:innen und Institutionen

  • Center for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Medical City, Abu Dhabi, UAE.
  • Department of Public Health & Epidemiology, Khalifa University, Abu Dhabi, UAE.
  • Division of Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA.
  • Campus of Haematology Franco and Piera Cutino, UOC Ematologia per le Malattie Rare Del Sangue e degli Organi Ematopoietici, AOOR Villa Sofia-V. Cervello, Palermo, Italy.
  • Laboratorio Biobanca, UOC Ematologia per le Malattie Rare Del Sangue e degli Organi Ematopoietici, Palermo, Italy.
  • UOSD Diagnostica Molecolare Malattie Rare Ematologiche, AOOR Villa Sofia-Cervello, Palermo, Italy.

ORCID-Profile: Khaled M Musallam, Angela Vitrano, Rosario Di Maggio, Maria Concetta Renda, Antonino Giambona, Efthymia Vlachaki, Paolo Ricchi, Filomena Longo, Aurelio Maggio

Förderung

  • Agios Pharmaceuticals Inc.
  • Agios Pharmaceuticals

Zitieren

APA

Musallam, K. M., Vitrano, A., Inzerillo, A., Di Maggio, R., Barone, R., Giangreco, A., Renda, M. C., Fecarotta, E., Troia, A., Giambona, A., Ruffo, G. B., Vlachaki, E., Venou, T. M., Ricchi, P., Ziello, B., Serra, M., Colizzi, E., Longo, F., Culcasi, M., & Maggio, A. (2026). Quantifying Morbidity Risk Attributed to Red‐Cell Transfusion Volume in Optimally Transfused Patients With β‐Thalassemia. American Journal of Hematology. https://doi.org/10.1002/ajh.70100

Vancouver

Musallam KM, Vitrano A, Inzerillo A, Di Maggio R, Barone R, Giangreco A, et al. Quantifying Morbidity Risk Attributed to Red‐Cell Transfusion Volume in Optimally Transfused Patients With β‐Thalassemia. American Journal of Hematology. 2026. doi:10.1002/ajh.70100

BibTeX
@article{Musallam2026,
  author = {Musallam, Khaled M and Vitrano, Angela and Inzerillo, Alessandro and Di Maggio, Rosario and Barone, Rita and Giangreco, Antonino and Renda, Maria Concetta and Fecarotta, Emanuela and Troia, Antonio and Giambona, Antonino and Ruffo, Giovan Battista and Vlachaki, Efthymia and Venou, Theodora M and Ricchi, Paolo and Ziello, Brunella and Serra, Marilena and Colizzi, Elena and Longo, Filomena and Culcasi, Martina and Maggio, Aurelio},
  title = {Quantifying Morbidity Risk Attributed to Red‐Cell Transfusion Volume in Optimally Transfused Patients With β‐Thalassemia},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70100}
}
Kostenlos starten →